It's one of the biggest disputes in biotech and a billion dollar question: Who owns the intellectual property behind CRISPR-Cas9, the groundbreaking gene-editing technology? The technique allows researchers to edit specific parts of a genome, removing, adding, or altering DNA. It could be the future of biotech, allowing everything from bespoke medical treatments to designer crops or even genetically superior Ubermenschen.
But both the University of California, Berkeley and the Broad Institute have claimed the technique as their own. Broad won an early battle in the USPTO in February, and now the conflict could be on its way up to the Federal Circuit.